No matter who sits in the White House over the next four years, a series of events has been triggered that could devastate millions of Americans. These events have caused five major cracks in our economy... That's why I have moved 7-figures of my own money out of the stock market.

Christopher Morabito net worth and biography

Christopher Morabito Biography and Net Worth

Insider of Fulcrum Therapeutics

Chris Morabito, MD has extensive leadership experience at biotechnology and pharmaceutical companies and has advanced discovery and clinical programs including Phase 1, proof-of-concept and pivotal studies. Most recently, he served as chief medical officer at Cardurion Pharmaceuticals where he oversaw all drug development activities. Prior to Cardurion, he served in several roles at Takeda, including program leadership and head of pipeline strategy, most recently serving as senior vice president and head of research and development for plasma-derived protein therapies. He also led programs from early development stage through regulatory submission at Sanofi and he began his career in industry at Merck & Co, leading development of multiple cardiovascular assets. Chris was also chief of the division of neonatology at Lehigh Valley Hospital and Health Network. He trained initially as a neonatologist at the University of California, San Francisco. He earned his B.A. in biology from Franklin and Marshall College, and his M.D. from Penn State University College of Medicine.

What is Christopher Morabito's net worth?: The estimated net worth of Christopher Morabito is at least $4,147.00 as of June 28th, 2021. Mr. Morabito owns 1,100 shares of Fulcrum Therapeutics stock worth more than $4,147 as of December 4th. This net worth evaluation does not reflect any other investments that Mr. Morabito may own. Learn More about Christopher Morabito's net worth.
How do I contact Christopher Morabito?: The corporate mailing address for Mr. Morabito and other Fulcrum Therapeutics executives is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. Fulcrum Therapeutics can also be reached via phone at (617) 651-8851 and via email at [email protected]. Learn More on Christopher Morabito's contact information.
Has Christopher Morabito been buying or selling shares of Fulcrum Therapeutics?: Christopher Morabito has not been actively trading shares of Fulcrum Therapeutics during the last ninety days. Most recently, on Monday, June 28th, Christopher Morabito bought 1,100 shares of Fulcrum Therapeutics stock. The stock was acquired at an average cost of $9.16 per share, with a total value of $10,076.00. Following the completion of the transaction, the insider now directly owns 1,100 shares of the company's stock, valued at $10,076. Learn More on Christopher Morabito's trading history.
Who are Fulcrum Therapeutics' active insiders?: Fulcrum Therapeutics' insider roster includes James Geraghty (Director), Robert Gould (Insider), Christopher Morabito (Insider), Curtis Oltmans (SVP), and Peter Thomson (CEO). Learn More on Fulcrum Therapeutics' active insiders.
Are insiders buying or selling shares of Fulcrum Therapeutics?: During the last year, insiders at the sold shares 2 times. They sold a total of 5,120 shares worth more than $59,071.84. The most recent insider tranaction occured on May, 7th when insider Greg Tourangeau sold 236 shares worth more than $1,831.36. Insiders at Fulcrum Therapeutics own 4.1% of the company. Learn More about insider trades at Fulcrum Therapeutics.
Information on this page was last updated on 5/7/2024.

Christopher Morabito Insider Trading History at Fulcrum Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/28/2021	Buy	1,100	$9.16	$10,076.00	1,100

Christopher Morabito Buying and Selling Activity at Fulcrum Therapeutics

Fulcrum Therapeutics Company Overview

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $3.77

$3.58

$3.88

50 Day Range

MA: $3.47

$2.97

$4.00

2 Week Range

Now: $3.77

$2.86

$13.70

Volume

721,973 shs

Average Volume

985,120 shs

Market Capitalization

$203.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.14

Even Trump can’t stop what’s coming.

From Behind the Markets | Ad

Watch my emergency briefing here >>>